Professor Jan Terje Andersen, Oslo University Hospital, will give a lecture on Antibody designs on 8 April from 16.00-17.00 in DDW-M2.01.
Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...
Denali Therapeutics regains full rights to investigational therapy DNL593 for GRN-related frontotemporal dementia: South San Francisco, California Tuesday, April 7, 2026, 12:00 Hr ...
Learn what the Nipah virus is, how it spreads, and why it has one of the highest fatality rates among infectious diseases.
Everyday Health on MSN
Beyond steroids: New myasthenia gravis treatment options offer hope for improved symptom control
Newer FDA-approved treatments for myasthenia gravis (MG) include FcRn blockers and complement inhibitors, which offer ...
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ ...
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved ...
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverag ...
Morning Overview on MSN
One-shot vaccine injected into tumors shows promise for boosting survival
A single injection of a redesigned immune-stimulating antibody directly into a tumor was linked to shrinkage not only at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results